Accelerating the identification & design of SARS-CoV2 antiviral drugs in combination with the “DrugDesign_SARS2” project

inSilico_Drugs_to_Beat_SARS2 project

Aim: to accelerate the identification & design of SARS-CoV-2 antiviral drugs in combination with the “DrugDesign_SARS2” project. FDA-approved Institut Pasteur Paris platforms, and subsequently, wide libraries of purchasable compounds will be screened in silico to target functions/interactions of RNA_Pol, Spike (virus targets) and ACE2 (host targets) proteins. Prioritization will accelerate testing & discovery of inhibitors. in silico modulation/optimization of validated hits will be pursued.

Back to top